The European Patent Office (EPO) has published patent application EP2026030759A1 concerning a polynucleotide influenza vaccine. The application, published on March 18, 2026, details a vaccine encoding hemagglutinin and neuraminidase, with relevant International Patent Classification (IPC) codes including A61K 39/145 and C12N 15/86. The designated states cover a broad range of European countries.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in vaccine development and intellectual property strategy. Companies operating in the EU should note this publication as it pertains to novel vaccine technology.